|
|
Profile
|
Delegates :
Kensuke Kato |
|
Incorporated :
May 29 , 2014 |
Paid in Capital :
Million yen |
Employees :
9 人 |
Address :
OFFICE-ONE Shijo Karasuma 11F 480, Niwatoriboko-cho, Shimogyo-ku KYOTO
〒6008491
|
TEL/FAX :
75-744-1114 / |
URL：
https://scad.or.jp/en/ |
Attachment :
 SCAD_business_summary_20240221.pdf [ 273.9KiB ] |
Mission/Background :
SCAD was established in May 2014 with the aim of practically available on the research outcomes of pluripotent stem cell (ES/iPS cell) research conducted at Kyoto University’s Institute for Frontier Medical Sciences (current Institute for Medical and Biological Sciences) and Institute for Integrated Cell-Material Sciences (iCeMS).
We are working to deepen the transferred technology and ensure sufficient reliability as a commercial technology through the participation of members with diverse knowledge and experience, and we are also actively promoting the global expansion of these businesses.
Currently, we are developing “cell therapy with Schwann cells” to regenerate damaged nerves and “iPS drug discovery” to explore new drug candidates using disease model cells derived from patients.
We will continue to return the results of our research to society toward the realization of a “new society created by stem cells". |
|
Technology & Business
|
# Cell Therapy
We have succeeded in stable production of matured Schwann cells from human pluripotent stem cells. Schwann cells are a type of nerve system cells that play crucial roles in nerve repair and regeneration. We are developing cell therapy for neuropathies and nerve injuries using Schwann cells, and currently, we have obtained non-clinical POC.
# iPS Drug Discovery
We are the first company in Japan to receive approval from the Japanese Government for the commercialization of drug discovery using iPS cells derived from human blood. Our drug discovery research aims to understand disease causes and identify therapeutic candidates using iPS cells generated from patients with intractable diseases.
# Cell Evaluation System
We have developed assay systems for cellular functions using our 3D culture methods and microengineered devices. Our approach enables higher-order functional tests that quantitatively evaluate cellular activities, such as nerve transmission and muscle contraction.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Repair of Nerve Injuries by Schwann Cell Therapy
|
Preclinical
|
Aim to regenerate damaged nerves by Schwann cells produced from allogeneic pluripotent stem cells. Animal POC has been obtained.
|
Establish cell production methods for clinical application.
|
iPS Drug Discovery
|
Preclinical
|
Establish iPS cell lines and conduct drug discovery research using patient-derived iPSCs for Charcot-Marie-Tooth disease.
|
|
Neural Cell Assay
|
Service/Marketing
|
Conduct contract/commissioned research utilizing our Schwann cells and 3D culture devices with oriented fiber scaffolds.
|
|
Muscle Cell Assay
|
Service/Marketing
|
Conduct contract/commissioned research utilizing 3D culture devices to quantitatively evaluates skeletal muscle contractility.
|
|
|
|
|
|
|
Highlights
|
August 2023: Commenced collaborative research with Kyoto University towards achieving Schwann cell-based regenerative medicine.
April 2023: Obtained U.S. patent rights for neural cell devices.
April 2023: Selected for a subsidy from the Ministry of Economy, Trade and Industry (METI).
March 2023: Initiated collaborative research with Kyoto University for translational research on neurological and muscular disorders.
December 2022: Published a paper on neural cell devices in Biomaterials Research.
|
|
Hot news
|
October 2023: Exhibited at BioJapan2023.
May 2023: Relocated our laboratory to the Kyoto University Med-Pharm Collaboration Bldg. (Innovation Hub Kyoto).
|
|
Alliance strategy
|
1) Seeking co-development and/or capital business alliance partners for our Schwann cell regenerative medicine, encompassing non-clinical research, clinical development, and manufacturing.
2) Seeking customers interested in contract/commissioned research utilizing our technologies.
|
|
|